Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Eisai Inc.
GI Innovation, Inc.
Eisai Inc.
Salubris Biotherapeutics Inc
Eisai Inc.